

## **The Angel Fund for ALS Research Announces "Angels Over Boston"**

### **International ALS Research Conference**

**Boston, MA — July 2026** — The Angel Fund for ALS Research will host **Angels Over Boston**, an international ALS research conference taking place July 14–16, 2026, in Boston. The conference will bring together leading scientists and clinicians from around the world who are dedicated to advancing research that will lead to effective treatments—and ultimately a cure—for Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s Disease.

The conference will focus on emerging therapeutic approaches to gene suppression therapy targeting mutations in the C9orf72 gene, the most common genetic cause of ALS. This important scientific gathering will foster collaboration and the exchange of groundbreaking research aimed at advancing promising therapies from the laboratory to patients.

The conference will be led by internationally recognized ALS researchers Prof. Robert H. Brown, Jr., DPhil, MD, Director of Neurotherapeutics at UMass Chan Medical School, and Prof. Daryl Bosco, Ph.D., Professor and Associate Vice Chair of Neurology at UMass Chan Medical School. Researchers and clinicians from the United States, Israel, and Germany will participate in this two-day scientific forum.

ALS remains a devastating and universally fatal neurodegenerative disease, with most patients surviving only three to five years following diagnosis. While the challenges remain immense, recent advances in genetics, biomarkers, and targeted therapies have created unprecedented momentum in the search for treatments.

"The urgency behind this work is deeply human," said Rich Kennedy, President of The Angel Fund for ALS Research. "Every ALS diagnosis begins an unrelenting race against time. Patients gradually lose the ability to walk, speak, swallow, and breathe, while remaining fully aware of the progression of the disease. For patients and caregivers, research represents more than scientific progress—it represents hope, dignity, and precious time."

Conferences like Angels Over Boston are essential because they accelerate the exchange of scientific ideas that may lead to earlier diagnosis, slower disease progression, and more effective therapies, continued Kennedy. By bringing together leading academic researchers and clinician-scientists from across the globe, we can help move promising discoveries closer to patients who need them the most and to shorten the path from scientific discovery to patient impact."

For more than 25 years, The Angel Fund for ALS Research has funded innovative, high-impact ALS research with a singular mission: improving outcomes for patients and families affected by ALS. Through conferences such as Angels Over Boston, The Angel Fund for ALS Research continues its commitment to advancing science and fostering collaborations that can transform hope into reality.

Organizations, foundations, and individuals interested in supporting Angels Over Boston are encouraged to contact The Angel Fund for ALS Research.

For sponsorship information, please contact:

**The Angel Fund for ALS Research**

Email: [theangelfundals@gmail.com](mailto:theangelfundals@gmail.com)

Phone: 617-823-1084

Together, we can **Step Up to Cure ALS**.

**About The Angel Fund for ALS Research**

The Angel Fund for ALS Research is dedicated to accelerating the discovery of effective treatments and a cure for ALS through innovative, patient-focused research. For more than 25 years, the organization has supported groundbreaking scientific initiatives and collaborations that bring hope to individuals and families impacted by ALS.

*The Angel Fund for ALS Research (Angel Fund, Inc – 04-3478977). is an independent 501(c)(3) nonprofit organization dedicated to supporting research into amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.*

*The Angel Fund’s mission is to raise funds through events, campaigns, foundation grants, and community outreach to support ALS research aimed at finding the cause, treatment, and cure for the disease . Our organization operates with minimal overhead—no rent, utility bills, or high-paid executives—allowing over 90% of its expenditures to directly fund research .*